Company news

PolTREG Spolka Akcyjna news in 2024

PolTREG Spolka Akcyjna's news releases, calls and decks from 2024, newest first.

View company

PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes

October 24, 2024

PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases

September 26, 2024

China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis

September 16, 2024

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence

September 9, 2024

PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years

June 24, 2024

PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab

April 4, 2024

PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland

March 11, 2024

PolTREG appoints Dan Shelly as Chief Business Development Officer

February 21, 2024

PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy

January 30, 2024

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

January 16, 2024

Decks in 2024